https://www.selleckchem.com/products/AZD8055.html
05. Mean ± SD activity counts during the third week of each treatment were significantly lower with amantadine (240,537 ± 53,88 compared with placebo (326,032 ± 91,759). CSOM scores assigned by the owners were significantly better with amantadine on the second (3 ± 1) and third (3 ± 1) weeks compared with placebo (5 ± 2 and 5 ± 1, respectively). A significantly greater proportion of owners reported improvement in quality of life with amantadine compared with placebo. Amantadine significantly decreased activity, but improved owner-iden
Like
Comment
Share
